Phase III Clinical Trials: Designing the Pivotal Evidence That Wins Regulatory Approval

Phase III is where a drug's development story either reaches its intended conclusion or ends. Everything that preceded it — the years of pre-clinical work, the Phase I safety characterization, the Phase II proof-of-concept and dose-finding — was preparation for this: a large, controlled, statistically rigorous demonstration that the drug produces meaningful clinical benefit in the patient population it is intended to treat, at the dose selected, measured by endpoints that regulators accept as valid measures of that benefit.

The demands of Phase III are unlike any other phase of clinical development. The trials are large — hundreds to thousands of patients. They run for years. They span dozens to hundreds of investigational sites across multiple countries. They generate datasets of extraordinary complexity. The regulatory submissions built on them — NDAs, MAAs, New Drug Applications to CDSCO — represent the culmination of a decade or more of scientific and clinical investment. And they must produce evidence that satisfies regulatory agencies, payers, and clinicians who will each evaluate the data from their own perspective and with their own criteria for what constitutes adequate proof.

Understanding what it takes to design a Phase III trial that succeeds across all of these audiences — and what the most common failures look like — is essential knowledge for every sponsor and clinical research professional.

The Fundamental Design Question: Superiority or Non-Inferiority?

The first and most consequential design decision in Phase III is the choice between a superiority design and a non-inferiority design. This choice determines the statistical hypothesis being tested, the comparator, the sample size, and the analysis methodology — and getting it wrong at this stage has no recovery.

Superiority trials test the hypothesis that the new drug is more effective than the control — whether that control is a placebo or an active comparator. Superiority is the gold standard for novel mechanisms entering treatment-naive indications, for drugs seeking to establish themselves as the preferred choice in a crowded therapeutic area, and for any situation where the new drug is genuinely expected to outperform what already exists.

Non-inferiority trials test the hypothesis that the new drug is not meaningfully worse than an established active comparator — specifically, that any loss of efficacy relative to the comparator does not exceed a pre-specified non-inferiority margin. The rationale for non-inferiority designs is that a drug can offer clinical value even if it does not improve efficacy — through a better tolerability profile, a more convenient route of administration, lower cost, or advantages in specific patient subgroups — provided that the reduction in efficacy, if any, is below a clinically meaningful threshold.

Non-inferiority trials typically require approximately four times the sample size of a comparable superiority trial with the same effect size — a consequence of the tighter statistical requirements for demonstrating equivalence within a margin rather than a directional treatment effect. The non-inferiority margin — the maximum acceptable loss of efficacy that still justifies the drug's clinical use — must be pre-specified, scientifically justified, and regulatorily agreed upon before the trial begins. Setting the margin too wide makes non-inferiority easy to demonstrate but clinically meaningless. Setting it too narrow produces a study that is unfeasibly large or that fails despite a genuinely adequate drug.

In non-inferiority trials, the analysis population choice inverts the usual superiority trial instinct. In superiority trials, the intention-to-treat population is conservative because dropouts and crossovers dilute the treatment effect. In non-inferiority trials that same dilution makes the two arms look more alike, biasing toward a false non-inferiority claim. Both ITT and per-protocol analyses must agree for a non-inferiority conclusion to be credible.

Endpoint Selection: The Regulatory Standard That Cannot Be Negotiated Away

The primary endpoint of a Phase III trial — the measure of clinical benefit on which the regulatory submission rests — must satisfy several requirements simultaneously: it must be clinically meaningful, validated as a measure of the intended benefit, reliably measurable across the multi-site, multi-country infrastructure of a Phase III program, and acceptable to the regulatory agency reviewing the submission.

Regulatory agencies have become progressively more specific and demanding about endpoint requirements in Phase III. FDA guidance documents for specific therapeutic areas define the endpoints that the agency considers adequate for each indication — and deviating from these guidance-recommended endpoints requires prospective regulatory agreement. CDSCO's increasing alignment with FDA and ICH guidance means that Indian submissions are subject to similar endpoint scrutiny.

The most consequential endpoint distinction in Phase III is between hard clinical endpoints — events that unambiguously represent clinical benefit or harm (mortality, hospitalisation, disease-free survival, confirmed disease progression) — and surrogate endpoints — measurable biological markers or intermediate outcomes that are expected to predict hard clinical outcomes but do not themselves represent the patient benefit of ultimate interest.

Hard clinical endpoints provide unambiguous regulatory credibility but require large sample sizes and long follow-up to accumulate adequate events. Surrogate endpoints allow smaller, shorter trials but carry the regulatory risk that the surrogate does not reliably predict the clinical outcome it is intended to represent. The history of Phase III is full of drugs that performed well on surrogate endpoints and were subsequently found to lack benefit — or even cause harm — on hard clinical outcomes.

Regulatory agencies have responded by raising the evidentiary bar for surrogate endpoint acceptance, particularly in indications where the consequence of approving an ineffective drug is severe. For any Phase III program using surrogate endpoints, the strength of the evidence linking the surrogate to the hard clinical outcome — and the regulatory agreement on this link — is a prerequisite for a credible regulatory strategy.

Multiplicity: Managing Multiple Endpoints and Hypotheses

Phase III trials routinely test multiple endpoints — a primary endpoint that drives the regulatory approval decision, secondary endpoints that characterize the drug's effect across other dimensions of clinical benefit, and exploratory endpoints that inform future development strategy. Managing the statistical implications of multiple hypothesis tests within a single trial — maintaining control of the overall Type I error rate while extracting the maximum informational value from the data — is one of the most technically demanding aspects of Phase III statistical design.

The pre-specified statistical analysis plan must define a testing hierarchy — an ordered sequence in which the primary endpoint is tested first, with secondary endpoints tested in pre-specified sequence only if the primary is positive. Endpoints outside the testing hierarchy are exploratory and cannot be used to support regulatory claims. The pre-specification must be locked before unblinding — any endpoint that is elevated to confirmatory status after the trial results are visible is subject to appropriate statistical correction and regulatory scrutiny.

Biomarker-defined subgroup analyses present additional multiplicity challenges. Regulators are appropriately skeptical of positive subgroup results that were not pre-specified — because with enough subgroups, any trial generates at least one positive result by chance. Pre-specified subgroup analyses with appropriate statistical power and a biologically justified rationale carry regulatory weight; post-hoc subgroup analyses do not, regardless of how compelling they appear.

Adaptive Phase III Designs: When Traditional Fixed Design Is Suboptimal

The traditional Phase III design — fixed sample size, fixed endpoints, fixed population, analysis at a single pre-specified endpoint — is appropriate for many situations. But adaptive designs have an increasingly established role in Phase III when the fixed design is inefficient or when specific scientific uncertainties justify building flexibility into the study.

Group sequential designs — the most widely implemented adaptive approach in Phase III — incorporate pre-specified interim analyses at which the trial can be stopped early for overwhelming efficacy (where continuing would be unethical given clear benefit), stopped for futility (where the probability of a positive result at full enrollment is below a pre-specified threshold), or continued to full enrollment. Stopping rules are defined using alpha spending functions that control the overall Type I error across all interim analyses.

Sample size re-estimation — adjustment of the planned sample size based on interim data about effect size or variability, without unblinding — addresses the uncertainty in sample size calculation at trial initiation. If the observed effect size at interim is smaller than projected, sample size can be increased (within pre-specified limits) to maintain statistical power. If variability is higher than anticipated, enrollment can be extended.

Adaptive enrichment — narrowing the enrolled population at a pre-specified interim based on accumulating efficacy data across biomarker-defined subgroups — allows a Phase III trial to start broad and become more focused as the evidence base develops.

All adaptive elements must be pre-specified before the trial begins, implemented by an independent data monitoring committee without compromising the blinding of the operational team, and statistically controlled to maintain Type I error integrity.

Multi-Country, Multi-Site Operations: The Operational Demands of Phase III

The scientific design of a Phase III trial is necessary but not sufficient. The operational execution — activating sites, enrolling patients, maintaining protocol compliance across diverse geographic, linguistic, and clinical practice contexts, managing data quality across thousands of case report forms, and ensuring safety reporting is timely and complete at every site — is where the difference between a successful Phase III and a failed one is often determined.

Site selection for Phase III is a strategic exercise. Sites must have access to sufficient eligible patients to meet their enrollment commitments, investigators must have the expertise and bandwidth to manage complex trial protocols, and the operational infrastructure — pharmacy, laboratory, data management — must be capable of sustaining the demands of a multi-year trial. The distribution of sites across geographies must reflect both operational logistics and the regulatory requirement that the Phase III population be representative of the patients who will ultimately use the drug if approved.

India has become an increasingly important component of global Phase III programs — for the patient access it provides across major therapeutic areas, for the cost efficiency of Indian site operations relative to Western alternatives, and for the increasingly regulatory-credible data that Indian GCP-compliant sites generate. The January 2026 NDCT amendments' 45-working-day review timeline for clinical trial applications, combined with India's well-established Phase III site infrastructure, makes India a competitive component of global Phase III networks.

Patient recruitment — which runs over for more than 80% of Phase III trials — is the most common operational failure in Phase III. Enrollment projections made at trial design are almost always optimistic, for predictable reasons: eligibility criteria are more restrictive in practice than on paper, site activation timelines are longer than planned, competing trials reduce site recruitment capacity, and patient willingness to participate varies with factors that are difficult to predict at trial design. The Phase III programs that meet their enrollment timelines are those that build realistic projections, monitor site performance in real time, and implement corrective interventions — additional site activation, targeted patient outreach, eligibility criteria amendment where supported by scientific rationale — before enrollment deficits become unrecoverable.

Data Quality, Integrity, and Inspection Readiness

The primary deliverable of a Phase III clinical trial is not the result — it is the data. Specifically, it is data that is attributable, legible, contemporaneous, original, accurate, complete, consistent, enduring, and available — the ALCOA+ principles that define regulatory-grade data quality and that FDA, EMA, and CDSCO inspectors apply when evaluating Phase III data packages.

The increasing use of electronic data capture, risk-based monitoring, and centralized data review in Phase III has substantially improved the efficiency of data quality management. But it has also shifted the locus of data quality assurance from the traditional model — monitoring individual site visits to identify and correct data errors — to a more sophisticated model of real-time, centralized data monitoring that detects patterns of potential data issues before they become systemic problems.

Protocol deviation management is a particular focus area in Phase III inspections. Major deviations from the protocol — enrollment of ineligible patients, protocol-prohibited concomitant medications, significant departures from the visit schedule, incomplete or incorrect informed consent procedures — can, in their most serious forms, require the exclusion of affected patients from the primary analysis, potentially compromising the statistical power of the trial. A comprehensive, timely, and documented deviation management process — identifying deviations at the time they occur, implementing corrective actions, and escalating patterns that suggest systematic site-level problems — is essential for maintaining the regulatory defensibility of Phase III data.

Regulatory Strategy and Scientific Advice

For any major Phase III program, engagement with regulatory agencies before the trial begins — through FDA's pre-Phase III meeting process, EMA's scientific advice and protocol assistance procedures, or CDSCO's scientific interaction mechanisms — is one of the highest-value investments in the development program. Regulatory agencies will evaluate the Phase III design against their published guidance and their experience with the specific indication, and providing advance notice of design decisions that deviate from guidance — with a well-developed scientific rationale — gives regulators the opportunity to identify concerns before the trial is enrolled rather than discovering them in the NDA review.

The regulatory questions that most benefit from advance scientific advice are endpoint selection (particularly where surrogate endpoints or novel PROs are proposed), patient population definition (particularly where the proposed population differs from that in existing guidance), the non-inferiority margin (if a non-inferiority design is planned), and the statistical analysis plan (particularly for adaptive designs).

Conclusion

Phase III is the most demanding, most expensive, and most consequential phase of clinical development. The scientific design must satisfy regulatory agencies, the operational execution must maintain data quality and protocol compliance across a global, multi-year enterprise, and the outcome must generate evidence that convinces not just regulators but clinicians, payers, and patients that the drug deserves a place in the standard of care.

The Phase III programs that succeed are those that invest equally in scientific design quality, operational execution capability, and regulatory strategy — recognizing that failures in any one of these domains can undermine the investment in the other two.

At Genelife Clinical Research, we support Phase III programs from study design and regulatory strategy through site activation, patient recruitment, data management, safety monitoring, and clinical study report preparation — in India and for international regulatory submissions to CDSCO, FDA, and EMA.

---

India's 2026 Clinical Trial Regulatory Reforms: What Small Molecule Sponsors Need to Know — and What Has Not Changed

In January 2026, India's Ministry of Health and Family Welfare published sweeping amendments to the New Drugs and Clinical Trials Rules 2019 — the governing framework for drug development and clinical research administered by CDSCO under the Drugs Controller General of India. According to CDSCO, the drug development lifecycle will see a minimum saving of 90 days. The amendments are now in effect and their impact on the country's pharmaceutical ecosystem is already being felt.

The coverage of these amendments in the pharmaceutical press has been enthusiastic — and in some cases, has created expectations that exceed what the reforms actually deliver. For international sponsors evaluating India as a clinical research destination, and for domestic pharmaceutical companies planning their development programs, an accurate understanding of what the 2026 amendments changed — and what they deliberately did not change — is more practically valuable than a headline summary.

This article provides that accurate understanding.

What the 2026 Amendments Actually Changed

The Prior Intimation Pathway — The Centerpiece of the Reform

The centerpiece of the reform is a deceptively simple shift: replacing the requirement for a formal test license with an online prior-intimation mechanism for most low-risk drug development and manufacturing activities.

Under the previous NDCT Rules, any company wishing to produce small quantities of a new or investigational drug — for research, non-clinical testing, analytical work, or bioequivalence studies — had to obtain prior manufacturing permission from CDSCO's Central Licensing Authority. This was an administrative approval process with its own timeline, documentation requirements, and potential for query-and-response delays. For a company managing multiple development programs simultaneously, the cumulative administrative burden was significant.

Under the amended Rule 52, the manufacture of a new drug or investigational new drug intended for analytical and non-clinical testing may now proceed upon submission of prior intimation in the prescribed form to the Central Licensing Authority and receipt of acknowledgement, without requiring substantive prior approval.

The practical effect: activities that previously required waiting for formal approval — manufacturing development batches for analytical testing, conducting stability studies, running non-clinical safety studies — can now begin faster, with the administrative gateway reduced to a notification and acknowledgement rather than a substantive regulatory review.

BA/BE Studies: A Significant Efficiency Gain for Generic Development

For bioavailability and bioequivalence studies, the reform is particularly significant. Under the previous framework, even low-risk BA/BE studies required prior regulatory permission from CDSCO before they could commence. The 2026 amendment eliminates this requirement for specified categories. Companies may now initiate these studies on the basis of a simple online intimation. CDSCO estimates it processes as many as 4,500 BA/BE applications annually; the new regime is expected to substantially reduce delays across this high-volume pipeline.

For India's generic pharmaceutical industry — which generates the majority of those 4,500 annual BA/BE applications — this is a meaningful operational improvement. Faster study initiation translates into faster regulatory submissions and faster market entry. The cumulative commercial value of this acceleration, multiplied across thousands of generic development programs, is substantial.

Reduced Review Timelines: 90 to 45 Working Days

A major reform introduced under the NDCT Amendment Rules 2026 is the reduction of regulatory review timelines from 90 to 45 working days.This represents a significant improvement for sponsors working on accelerated development programs, rare disease therapies, biosimilars, or repurposed drugs where the development timeline is a critical commercial variable.

The qualification here matters, however: this is a statutory maximum, not a guaranteed outcome. The 45-working-day review window assumes a complete, well-prepared submission that does not generate significant regulatory queries. A submission that triggers query-and-response cycles — because documentation is incomplete, the clinical rationale is inadequately developed, or the ethics committee approval is not yet in place — will consume most or all of the statutory period in those cycles. The quality of the submission dossier remains the primary determinant of actual review time.

Terminology Harmonization

The 2026 amendments introduce consistent terminology across Rules 52–66, clearly distinguishing between different regulatory pathways and formalizing both prior-approval and prior-intimation routes. This harmonization, while less headline-worthy than the timeline reductions, reduces the ambiguity in the existing rules that has historically been a source of interpretation inconsistency — both within CDSCO and across the sponsor community.

What Has Not Changed — The Misreadings to Avoid

The enthusiasm with which the 2026 amendments have been received has produced some misreadings that could create problematic expectations for sponsors who act on them. Here are the most important clarifications.

Clinical Trial Approval for Phase I, II, and III Studies: Unchanged

This is the most consequential point for small molecule clinical development sponsors. The prior intimation pathway introduced by the 2026 amendments applies to manufacturing and non-clinical activities — not to clinical trial initiation. The 2026 amendment does not speed up trial approval itself. A clinical trial cannot enrol its first participant until both the DCGI's clinical trial permission and a registered Ethics Committee's approval are in place.

Phase I, II, and III clinical trial applications for new drugs still require formal CDSCO approval under the IND/CT pathway before the first participant can be enrolled. The ethics committee review process is separate, simultaneous, and also required before enrolment. Neither of these requirements has been changed by the 2026 amendments.

The practical implication: sponsors who read the reform as accelerating the pathway to enrolling the first patient in a clinical trial will be disappointed. The timeline from clinical trial application to first patient enrolled — which involves CDSCO review, ethics committee review, site activation, and participant recruitment — is not materially different under the 2026 rules than it was before.

High-Risk Drug Categories: Unchanged

High-risk drug categories — including sex hormones, cytotoxic drugs, beta-lactam antibiotics, biologics containing live microorganisms, and narcotic and psychotropic substances — continue to require prior regulatory approval. The prior intimation pathway is explicitly risk-proportionate: it applies to lower-risk activities where regulatory pre-screening adds administrative burden without proportionate safety benefit. For the categories where the risk justifies substantive pre-approval, that requirement has been maintained.

Ethics Committee Requirements: Unchanged and Strengthened

The ethics committee oversight framework that has been progressively strengthened since the 2013 clinical trial regulatory reforms remains fully in place. All clinical studies involving human participants require prior ethics committee approval from a CDSCO-registered ethics committee. The informed consent requirements, the SAE reporting timelines, the audit and inspection framework, and the participant compensation rules are unchanged.

What the 2026 Reform Means for International Sponsors

For international pharmaceutical and biotech companies evaluating India as a location for clinical development activities, the 2026 amendments improve India's competitive position in specific and well-defined ways.

Pre-clinical and manufacturing activities are faster. For programs in active pre-clinical development, the ability to begin non-clinical safety studies, analytical method development, and formulation work without waiting for manufacturing approval removes a procedural delay that could previously add weeks to the development timeline. For international sponsors running parallel programs across multiple geographies, this administrative streamlining reduces the friction of including India in the pre-clinical development pathway.

BA/BE programs are more efficient. For generic pharmaceutical companies filing ANDAs in the US or seeking generic approvals in the EU, India's BA/BE infrastructure — established clinical sites, experienced investigators, cost-competitive analytical laboratories — combined with the streamlined prior-intimation pathway makes India an even more attractive location for BE study conduct than it was before. The combination of operational excellence and reduced administrative overhead strengthens India's position as the preferred global destination for BA/BE work.

The clinical trial pathway remains what it was — rigorous and requiring quality preparation. International sponsors should calibrate their India timelines accordingly. The clinical trial application process, while operating under a reduced statutory maximum of 45 working days, still requires a complete, high-quality submission. The ethics committee review runs in parallel and has its own timeline. Site activation, investigator contracting, and participant recruitment follow approval. Building these realistic timelines into program planning — rather than assuming that the 2026 reforms have transformed India into a low-friction regulatory environment for clinical trial initiation — produces more reliable project plans and more credible investor timelines.

The Broader Context: India's Regulatory Trajectory

The 2026 NDCT amendments do not stand alone. They are the latest step in a regulatory reform trajectory that has been building since the early 2010s — a sustained effort to modernize India's clinical research regulatory framework while maintaining the safeguards appropriate to a country that hosts a significant and growing proportion of global clinical development activity.

The reform is explicitly risk-proportionate: lighter regulation for lower-risk activities and maintained oversight where the stakes are higher. This principle — which aligns with the risk-based regulatory philosophy that the FDA, EMA, and ICH have been promoting globally — represents a genuine maturation of India's regulatory thinking, not merely a simplification of procedure.

For the international clinical research community, the direction of India's regulatory evolution is as important as any specific amendment. A regulator that is progressively aligning its framework with international risk-based principles, reducing administrative overhead for low-risk activities while maintaining rigorous oversight for high-risk ones, and committing to shorter review timelines is a regulator that is building confidence for long-term partnership.

The 2026 amendments are a meaningful step in that direction. Their appropriate value for sponsors is as evidence of that trajectory — not as a transformation of India's regulatory landscape into something categorically different from what it was before.

Practical Guidance for Sponsors

For generic pharmaceutical companies and BA/BE programs: The prior intimation pathway is immediately beneficial. If your development pipeline includes BA/BE studies for ANDA or generic regulatory submissions, the 2026 amendments remove a meaningful administrative delay. Engage a CRO partner familiar with the new SUGAM portal procedures and the intimation documentation requirements to ensure a smooth transition to the new pathway.

For new chemical entity sponsors planning Indian Phase II or III sites: The clinical trial approval pathway is unchanged. Build your India site activation timeline on realistic CDSCO review expectations — quality submission plus 45-working-day statutory maximum, with ethics committee review running in parallel. A well-prepared, complete submission to both CDSCO and the ethics committee simultaneously is the most effective timeline optimization available.

For Indian pharma companies with domestic NCE programs: The combination of the prior intimation pathway for pre-clinical work and the reduced 45-working-day review timeline for clinical trial applications is genuinely beneficial. The most important factor in realizing these improvements is submission quality — a complete, well-documented application that does not generate avoidable queries from CDSCO reviewers.

For international sponsors considering India for Phase I studies: The Phase I pathway remains governed by the requirement to have prior Phase I data from the country of origin for foreign-discovered compounds. The 2026 amendments do not change this. For India-discovered NCEs, however, the streamlined pre-clinical pathway improves the efficiency of the pre-Phase I development work.

Conclusion

India's 2026 NDCT amendments are a genuine improvement to the regulatory framework for drug development — meaningful, well-targeted, and consistent with the international direction of risk-proportionate regulatory reform. The savings in administrative time for pre-clinical, manufacturing, and BA/BE activities are real and practically significant.

What they are not is a transformation of India's clinical trial initiation pathway for new drug substances. Phase I, II, and III clinical trial approval remains a substantive regulatory review process that requires a complete, high-quality application and realistic timeline planning.

For sponsors who understand the reform accurately — who capture the genuine efficiencies it offers while planning clinical trial timelines on the basis of what the process actually requires — the 2026 amendments are a meaningful enhancement to India's already strong position as a global clinical research destination.

At Genelife Clinical Research, we have been navigating CDSCO's regulatory processes for 16 years and have deep operational familiarity with both the new prior intimation procedures and the clinical trial approval pathway as it functions in practice. We help sponsors build accurate, achievable timelines and prepare submissions that minimize query cycles and maximize the probability of first-cycle approval.

---

To learn more about Genelife's regulatory strategy and clinical development services in India, visit genelifecr.com.

Related Insights

Clinical Trial Process in India: Step-by-Step Guide

CDSCO Approval Process for Clinical Trials in India: Complete Guide

What is a CRO? Role of Clinical Research Organizations in India

Learn more about our clinical research services for end-to-end clinical trial support.

Drug Repurposing: Why the Pharmaceutical Industry's Best New Drugs May Already Exist

 The conventional narrative of drug discovery runs in one direction: a novel compound is identified, optimized, tested, and — if everything goes well — approved. The molecule is new. The target is new. The therapeutic indication is new. The development timeline is long, the attrition is high, and the cost is enormous.

Drug repurposing runs the same process in reverse. The molecule already exists. Its safety profile in humans is already known. Its manufacturing process is established. The question is not whether it is safe to give to people — that has been answered — but whether it does something useful in a disease for which it was not originally developed.

This is not a niche strategy. Historical examples include sildenafil citrate transitioning from a cardiovascular compound to an erectile dysfunction treatment, and thalidomide shifting from a sedative to a foundational immunomodulatory agent in multiple myeloma — drugs that found their most important clinical applications not in the indications for which they were designed, but in diseases discovered through observation, serendipity, and scientific curiosity. These are not outliers. They are the clearest illustrations of a principle that the pharmaceutical industry is now pursuing systematically: the biology of existing drugs is richer than their approved labels suggest.

Why Drug Repurposing Has Accelerated

Several converging forces have made drug repurposing more scientifically tractable and more commercially attractive than at any previous point in the industry's history.

The explosion of biological and clinical data available for analysis has transformed what is possible. By leveraging the established safety and efficacy profiles of existing drugs, repurposing can significantly reduce the time, cost, and risk associated with traditional drug development, while providing a valuable pathway for addressing unmet medical needs. But the practical ability to identify repurposing opportunities at scale has historically been limited by the difficulty of systematically mining the relevant data — preclinical pharmacology, clinical adverse event patterns, transcriptomic signatures, network pharmacology relationships — across thousands of approved compounds simultaneously.

Artificial intelligence has changed that. AI-based platforms can analyze gene expression data, protein interaction networks, electronic health records, adverse event databases, and published literature at a scale and speed that no human team can match — identifying pharmacological relationships between approved drugs and disease pathways that would be invisible to conventional analysis. The same generative AI capabilities driving the discovery of new compounds like Rentosertib are increasingly being applied to the repurposing of existing ones.

The COVID-19 pandemic provided the most dramatic demonstration of drug repurposing at accelerated scale. The urgent search for COVID-19 treatments generated an extraordinary volume of repurposing clinical trials — with more than 4,952 clinical trials registered on ClinicalTrials.gov by March 2021, evaluating existing drugs including remdesivir, dexamethasone, baricitinib, and tocilizumab. The outcomes were mixed, but the exercise validated the clinical research infrastructure for rapid repurposing evaluation and produced genuine therapeutic discoveries — dexamethasone's role in reducing COVID-19 mortality being the most consequential.

Most recently, nitisinone — a compound originally developed as a herbicide and later approved for hereditary tyrosinemia type 1 — received FDA approval in 2025 for alkaptonuria, becoming the first targeted therapy for this ultra-rare metabolic disease after 25 years of research. The molecule was not new. The clinical need it addressed was profound and previously unmet.

The Clinical Development Advantage — and Its Limits

The most compelling aspect of drug repurposing from a development perspective is what does not need to be done. Toxicology studies across multiple species. Safety pharmacology assessments. Manufacturing process development. First-in-human dose escalation studies to establish maximum tolerated dose and pharmacokinetic profile.

For an approved drug being evaluated in a new indication, much of this pre-clinical and Phase I work is already complete. The known safety profile means that Phase II proof-of-concept studies can sometimes begin with a level of confidence in the compound's tolerability that a novel molecule cannot offer. The known pharmacokinetics mean that dose selection for the new indication can build on an established human data foundation rather than extrapolating from animal models.

Access to drugs already approved enables off-label clinical studies without the need for new GMP production, lowering trial barriers. The manufacturing supply chain is established. Regulatory submissions can reference the existing safety dossier rather than building a new one from scratch.

These advantages are real and significant. But they come with constraints that define what repurposing clinical programs need to do differently from conventional new drug development.

The indication specificity challenge. An approved drug's safety profile was characterized in a specific patient population, at a specific dose, for a specific duration of use. The new indication may involve a different patient population with different comorbidities, different concomitant medications, and different baseline organ function. The safety data from the original indication cannot be assumed to fully characterize the risk in the new indication. Phase II and III programs for repurposed drugs must include safety evaluation appropriate to the new patient population — not simply reference the existing label.

The dose may be different. The dose that was optimal for the original indication may not be optimal — or even appropriate — for the new one. Sildenafil for pulmonary arterial hypertension is dosed very differently from sildenafil for erectile dysfunction. Thalidomide's immunomodulatory applications require dose regimens that would not have been derived from its original sedative use. The clinical program for a repurposed drug must establish the appropriate dose for the new indication — which may require dose-finding studies that parallel the Phase I/II work done for the original compound.

The mechanism may be different. One of the most scientifically interesting aspects of drug repurposing is that the mechanism of action in the new indication may not be the same as in the original one. Repurposed drugs such as metformin and minoxidil demonstrate the clinical potential of repositioning strategies guided by mechanistic insight, phenotypic screening, and real-world observations — where the observed clinical effect in a new context reveals biology that was not the original pharmacological target. Understanding the mechanism of action in the new indication is important both for clinical development strategy and for regulatory submission — regulators will want to understand why the drug works in the new context, not just whether it does.

---

Regulatory Pathways for Repurposed Drugs

The regulatory landscape for drug repurposing is more nuanced than the simplified narrative of "already approved, therefore easier to develop" suggests.

In the United States, a repurposed drug seeking a new indication requires a supplemental NDA if the original sponsor is pursuing the new indication, or a full NDA or 505(b)(2) application if a different company is developing the new indication. The 505(b)(2) pathway — which allows reliance on the FDA's existing findings of safety and effectiveness for a previously approved drug — is the most commonly used regulatory mechanism for repurposing by non-originators. It requires the sponsor to demonstrate that the referenced data is scientifically appropriate for the new application and to address any differences in population, dose, route, or formulation.

The FDA's stance on real-world evidence for repurposing has shifted dramatically in recent years. In December 2025, FDA eliminated a major barrier by stating that submissions need not include individual-level patient data from real-world data sources — and a May 2026 initiative opened stakeholder input on using case reports, observational studies, and registry data as components of the repurposing evidence package. This evolution makes the regulatory pathway for repurposing, particularly in rare diseases and underserved indications, meaningfully more accessible than it was even five years ago.

In India, CDSCO's framework for repurposing is evolving. For drugs already approved in India being evaluated for new indications, the regulatory pathway builds on the existing drug master file, with the clinical trial application for the new indication evaluated in the context of the established safety dossier. The January 2026 NDCT amendments, which streamlined several regulatory processes, are beneficial for repurposing programs that involve BA/BE studies or non-clinical testing — reducing the administrative overhead at the early development stages.

---

India as a Location for Drug Repurposing Clinical Programs

India's clinical research infrastructure offers several specific advantages for drug repurposing programs that are worth understanding explicitly.

Disease prevalence and population diversity. Many of the most interesting repurposing opportunities — metabolic disease, fibrotic conditions, inflammatory disorders, rare genetic diseases, infectious disease — are prevalent in India at high rates, providing the patient access needed for efficient clinical proof-of-concept evaluation. Drug repurposing successes in rare diseases, including nitisinone for alkaptonuria and sirolimus for rare vascular anomalies, illustrate the value of patient populations that are rare globally but may be more accessible in India's large and diverse population.

Cost and speed for proof-of-concept. The Phase II proof-of-concept study is often the most critical and most cost-sensitive stage of a repurposing program — the study that determines whether the investment in a full Phase III program is justified. Conducting these studies in India at 40 to 60 percent of Western costs, with faster site activation and recruitment timelines, substantially improves the economics of repurposing programs that may be pursued by academic groups, patient advocacy organizations, or small biotech companies rather than large pharmaceutical sponsors.

AI-supported target identification. AI algorithms are transforming drug repurposing by revealing new therapeutic targets and mechanisms — and the integration of omics data with computational modeling enhances target identification and validation in repurposing studies. Indian research institutions and bioinformatics groups are increasingly active in this space, creating opportunities for academic-industry collaborations that identify repurposing candidates and partner with CROs to translate them into clinical programs.

---

What Drug Repurposing Programs Need From a Clinical Research Partner

A CRO supporting a drug repurposing clinical program needs to bring a specific combination of capabilities that differs from conventional new drug development support.

Regulatory strategy for the new indication, building on but not simply referencing the existing approval, requires regulatory expertise in the repurposing pathway — 505(b)(2) in the US, the analogous mechanisms in the EU and India — and the scientific judgment to identify what the new clinical program must demonstrate and what it can appropriately reference from the existing dossier.

Clinical study design for proof-of-concept in the new indication requires understanding of the disease biology, the appropriate patient population, and the endpoints that are validated in the new therapeutic context — which may be quite different from the endpoints used in the original indication's development program.

Safety monitoring designed for the new population — not simply referenced from the existing label — requires pharmacovigilance expertise and the clinical judgment to identify where the safety assumptions from the original indication may not fully apply.

And the biomarker strategy — confirming that the repurposed drug is engaging its target in the new indication and producing the expected pharmacodynamic effect — is often more important in repurposing programs than in conventional development, because the mechanism of action in the new context may not be as well established as in the original indication.

Conclusion

Drug repurposing is not a shortcut. It is a scientifically rigorous and commercially intelligent strategy for accelerating the delivery of medicines to patients who need them — by building on the biological knowledge embedded in existing drugs rather than starting from zero. The savings in time, cost, and pre-clinical work are real. The clinical development work that remains — proving efficacy in the new indication, establishing the appropriate dose, characterizing safety in the new patient population, and navigating the regulatory pathway — is substantial and requires exactly the same scientific and operational rigor as conventional drug development.

The difference is that repurposing programs start from a place of greater biological knowledge. Used well, that head start can transform the economics and the timeline of clinical development in ways that benefit not just sponsors and developers, but the patients waiting for the therapies they need.

At Genelife Clinical Research, we support Phase II and III clinical programs for repurposed small molecules — from regulatory strategy and proof-of-concept study design through clinical execution, statistical analysis, and regulatory submission support — in India and for international markets.